Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to $40.6 million.

  • Keros Therapeutics' Shares Outstanding (Weighted Average) rose 8.24% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 8.24%. This contributed to the annual value of $40.5 million for FY2024, which is 35.21% up from last year.
  • Keros Therapeutics' Shares Outstanding (Weighted Average) amounted to $40.6 million in Q3 2025, which was down 0.00% from $40.6 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Shares Outstanding (Weighted Average) registered a high of $40.6 million during Q2 2025, and its lowest value of $23.3 million during Q1 2021.
  • In the last 3 years, Keros Therapeutics' Shares Outstanding (Weighted Average) had a median value of $36.1 million in 2024 and averaged $35.4 million.
  • Data for Keros Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 35.21% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Keros Therapeutics' Shares Outstanding (Weighted Average) stood at $23.4 million in 2021, then grew by 17.71% to $27.5 million in 2022, then grew by 8.77% to $30.0 million in 2023, then skyrocketed by 35.21% to $40.5 million in 2024, then rose by 8.24% to $40.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $40.6 million for Q3 2025, versus $40.6 million for Q2 2025 and $40.6 million for Q1 2025.